Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2025)

CG Oncology's Total Non-Current Liabilities history spans 3 years, with the latest figure at $37.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 73.9% year-over-year to $37.2 million; the TTM value through Dec 2025 reached $37.2 million, up 73.9%, while the annual FY2025 figure was $37.2 million, 73.9% up from the prior year.
  • Total Non-Current Liabilities reached $37.2 million in Q4 2025 per CGON's latest filing, down from $38.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $38.5 million in Q3 2025 to a low of $14.1 million in Q4 2023.
  • Average Total Non-Current Liabilities over 3 years is $27.8 million, with a median of $29.3 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 51.42% in 2024, then surged 73.9% in 2025.
  • A 3-year view of Total Non-Current Liabilities shows it stood at $14.1 million in 2023, then soared by 51.42% to $21.4 million in 2024, then soared by 73.9% to $37.2 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Total Non-Current Liabilities are $37.2 million (Q4 2025), $38.5 million (Q3 2025), and $21.4 million (Q4 2024).